Corrigendum: Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy

Corrigendum: Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy

Bibliographic Details
Main Authors:	Ni Zhao, Ye Yi, Wen Cao, Xiao Fu, Nan Mei, Chunli Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Oncology
Subjects:	biomarkers cytokines immunotherapy lung cancer immune related adverse events
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1069999/full

Similar Items

Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
by: Ni Zhao, et al.
Published: (2022-08-01)

Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors
by: Hannah Schindler, et al.
Published: (2022-10-01)

Adverse Events of Oncologic Immunotherapy and Their Management
by: Fedricker Diane Barber
Published: (2019-01-01)

Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
by: Dung-Tsa Chen, et al.
Published: (2023-04-01)

Rheumatological Adverse Events Following Immunotherapy for Cancer
by: Ioana Cretu, et al.
Published: (2022-01-01)

Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases
by: Jean-Matthieu L’Orphelin, et al.
Published: (2021-09-01)

Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
by: Víctor Albarrán-Artahona, et al.
Published: (2022-08-01)

Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors
by: Jingting Wang, et al.
Published: (2024-01-01)

Occurrence and Management of Immunotherapy-Associated Adverse Events in Patients with Gynecological Cancers
by: Ina Shehaj, et al.
Published: (2024-03-01)

Discontinuation risk from adverse events: immunotherapy alone vs. combined with chemotherapy: a systematic review and network meta-analysis
by: Sangwon Shin, et al.
Published: (2024-01-01)

Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies—Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology taskforce
by: Julijana Asllani, et al.
Published: (2023-06-01)

Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy
by: Haowei Wang, et al.
Published: (2022-02-01)

Immunogenomic correlates of immune-related adverse events for anti–programmed cell death 1 therapy
by: Lei Zhang, et al.
Published: (2022-11-01)

Balancing the Risk of Adverse Events against the Efficacy of Immunotherapy in Advanced Thymic Epithelial Tumors
by: Birte Ohm, et al.
Published: (2022-12-01)

Behavioral, Psychiatric, and Cognitive Adverse Events in Older Persons Treated with Glucocorticoids
by: Ciro Manzo, et al.
Published: (2018-08-01)

Incidence of Skin and Respiratory Immune-Related Adverse Events Correlates With Specific Tumor Types in Patients Treated With Checkpoint Inhibitors
by: Lynn M. Rose, et al.
Published: (2021-01-01)

Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use
by: Yuchen Li, et al.
Published: (2024-01-01)

Characteristics of dust mite sublingual immunotherapy-associated adverse events in the early phase
by: Ming Chen, et al.
Published: (2022-12-01)

A Single Center Analysis of Advanced Non-small Cell Lung Cancer Patients Treated with Immunotherapy in Real-world Practice
by: Yanxia LIU, et al.
Published: (2019-11-01)

Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit
by: Adrien Joseph, et al.
Published: (2020-10-01)

Adverse events during immunotherapy in Slovenian patients with metastatic melanoma reveal a positive correlation with better treatment outcomes
by: Mesti Tanja, et al.
Published: (2021-05-01)

Adverse events of neoadjuvant combination immunotherapy for resectable cancer patients: a systematic review and meta-analysis
by: Yuqian Feng, et al.
Published: (2024-01-01)

Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer
by: Michael Burke, et al.
Published: (2021-09-01)

Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
by: Xiaoyan Si, et al.
Published: (2020-03-01)

Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers
by: Yanni Wang, et al.
Published: (2022-09-01)

Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors
by: Ben Ponvilawan, et al.
Published: (2024-03-01)

Editorial: Immune-Related Adverse Events for Patients With Lung Cancer
by: Ruoning Yang, et al.
Published: (2022-05-01)

Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis
by: Xiao-Tong Zhang, et al.
Published: (2022-11-01)

Predictive Role of Prior Radiotherapy and Immunotherapy-Related Adverse Effects in Advanced NSCLC Patients Receiving Anti-PD-1/L1 Therapy
by: Jeong Uk Lim, et al.
Published: (2021-08-01)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
by: Bin Zhao, et al.
Published: (2018-10-01)

A Real-world Study on the Incidence and Outcome of Immune-related Adverse Events in Lung Cancer Patients
by: Shaohua CUI, et al.
Published: (2023-04-01)

Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer
by: Max Hardy-Werbin, et al.
Published: (2019-06-01)

Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry
by: Lina María Serna-Higuita, et al.
Published: (2021-12-01)

Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
by: Maria Kowalska, et al.
Published: (2016-05-01)

Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer
by: Yinghao Zhao, et al.
Published: (2023-02-01)

Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators
by: Marco Stellato, et al.
Published: (2021-08-01)

Adverse Childhood Events and Health Biomarkers: A Systematic Review
by: Sara Soares, et al.
Published: (2021-08-01)

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
by: Yanting Zhou, et al.
Published: (2023-06-01)

A Review of Bullous Dermatologic Adverse Events Associated with Anti-Cancer Therapy
by: Rose Parisi, et al.
Published: (2023-01-01)

Cutaneous Adverse Events to Targeted Therapies and Immunotherapies in Children: A Retrospective Study of 103 Patients from Two Tertiary Haemato-Oncology Referral Centres
by: Ayelet Ollech, et al.
Published: (2021-07-01)